Tam Moses, Riaz Nadeem, Salgado Lucas Resende, Spratt Daniel E, Katsoulakis Evangelia, Ho Alan, Morris Luc G T, Wong Richard, Wolden Suzanne, Rao Shyam, Lee Nancy
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
J Radiat Oncol. 2013 Sep;2(3):285-291. doi: 10.1007/s13566-013-0107-6. Epub 2013 Jul 10.
Excellent local-regional control can be achieved for major salivary gland tumors treated with surgery and post-operative radiotherapy. We evaluated the cumulative incidence and predictors of distant metastasis in high-risk major salivary gland tumors.
Between 1990 and 2011, 200 patients with major salivary gland tumors received post-operative radiotherapy at our center. The patients' median age was 60 years. Patients had primary tumors of the parotid gland (84%), submandibular (16%), and one sublingual gland. Among the patients, 34% had T3-T4 tumors, 32% had nodal involvement. Other high-risk features included close/positive margins and high grade tumors. The median RT dose was 63 Gy.
With a median follow-up of 50 months, the 5-year local control and regional control were 88% and 94%, respectively. The 5-year freedom from distant metastasis was 73%. The median overall survival was 14.6 years corresponding to a 5 and 10-year overall survival of 77% and 59%, respectively. T category and nodal involvement were independent predictors of distant metastasis. Nodal involvement was also an independent predictor of overall survival.
Distant relapse was the predominant mode of failure despite excellent local-regional control in high-risk major salivary gland tumors. Both advanced T category and nodal involvement were independent predictors of distant metastasis. More effective systemic therapy is needed to combat distant relapse.
手术联合术后放疗可实现对大唾液腺肿瘤的良好局部区域控制。我们评估了高危大唾液腺肿瘤远处转移的累积发生率及预测因素。
1990年至2011年间,200例大唾液腺肿瘤患者在我们中心接受了术后放疗。患者的中位年龄为60岁。患者的原发肿瘤位于腮腺(84%)、下颌下腺(16%)和1例舌下腺。其中,34%的患者患有T3 - T4期肿瘤,32%的患者有淋巴结受累。其他高危特征包括切缘接近/阳性和高级别肿瘤。中位放疗剂量为63 Gy。
中位随访50个月,5年局部控制率和区域控制率分别为88%和94%。5年无远处转移生存率为73%。中位总生存期为14.6年,5年和10年总生存率分别为77%和59%。T分期和淋巴结受累是远处转移的独立预测因素。淋巴结受累也是总生存期的独立预测因素。
尽管高危大唾液腺肿瘤的局部区域控制良好,但远处复发是主要的失败模式。T分期进展和淋巴结受累都是远处转移的独立预测因素。需要更有效的全身治疗来对抗远处复发。